

CURRICULUM VITAE

Name Schuurman, Hendrik-Jan
Address 81 Frederik Hendrikstraat, 3583 VH Utrecht, The Netherlands
Phone +31 6 3195 3962
Born July 11, 1950 (Enschede, The Netherlands)
Citizenship Netherlands
Civil status Married
Email schubiomed@gmail.com

Training/Certification

1977 Ph.D. degree, Faculty of Science, University of Utrecht, The Netherlands
1974 Graduate in Chemistry, University of Utrecht
Certification Immunology (1980), Clinical (Medical) Immunology (1981), Experimental Pathobiology (1990)

Employment and Experience

2010- Consultant and Director, SchuBiomed Consultancy (Utrecht, the Netherlands)

Consultant in the biomedical sector, in particular transplantation and xenotransplantation, with focus on advanced nonclinical research leading to first-in-man trials, including regulatory aspects and animal modeling (translational value).

2010-2012 Senior Vice President, Beta-Cell NV (Brussels, Belgium)

Beta-Cell is a spin-off from the Diabetes Research Center at Brussels Free University, with the mission to develop proprietary cell therapeutics for treatment of diabetes. The first product is BetaGRAFT, i.e. encapsulated islets from human or porcine origin. Dr Schuurman worked closely with the CEO of Beta-Cell in a series B financing, and achieved regulatory approval of a source of donor animals.

2006-2010 Chief Executive Officer, Spring Point Project (Minneapolis, MN, USA) Professor of Surgery and Co-Director for Preclinical Studies, Schulze Diabetes Institute, Department of Surgery, University of Minnesota (Minneapolis, USA)

Spring Point Project is a 501(c)(3) tax-exempt non-profit entity whose mission is to 'to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes' (www.springpointproject.org). The work is conducted in partnership with the University of Minnesota's Schulze Diabetes Institute, based on substantial achievements in providing suitable islets for clinical trials and results in preclinical studies. Dr Schuurman guided Spring Point Project (~10FTE) during the phase of design and construction of an animal facility and the population of this facility till a stable operation and pig production: in the Schulze Diabetes Institute he was directly involved in the design, conduct and interpretation of translational experimental animal research in preparation for clinical trials, and supervised a PhD thesis.

2004-2006 Director, BioMedical Research, Numico Research BV (Wageningen, NL)

Royal Numico is a high-growth, high-margin specialised nutrition company with leading positions in Baby Food and Clinical Nutrition. In 2007 Royal Numico was acquired by the Danone Group and renamed Danone Baby and Medical Nutrition B.V. The company develops innovative nutrition products for a better and healthier life, as shown in laboratory investigations and clinical trials. Located in Wageningen-The Netherlands, the BioMedical Research Department (~50 FTEs) conducts fundamental research in the fields of Microbiology, Immunology, Cell Biology, Physiology, and Gut Biology, in projects that are research-driven but consumer-led. As member of the management team, Dr Schuurman had the task to provide a smooth and efficient translation of fundamental research data into new high-quality products to create economic value within the shortest timelines possible.

2001-2004 Vice President Research, Immerge BioTherapeutics, Inc (Boston, MA, USA)

Immerge, a joint venture of Novartis and BioTransplant Incorporated, was a small biotechnology company (~20FTE) with the mission to develop porcine cells, tissues and organs for end-stage organ failure and diabetes, utilizing a safe therapeutic paradigm, focusing on research in preclinical transplantation models, safety aspects, and animal genetic engineering. Dr. Schuurman has successfully implemented a program on islet cell xenotransplantation for the treatment of diabetes. A small-sized research program has provided major achievements, leading to the proposal to progress to first clinical studies in diabetic patients. Dr Schuurman directed the research in three groups (total ~15FTE): animal genetic engineering, porcine retrovirology, and immunology.

1999-2000 Head of Unit and Programme 'Primate xenotransplantation', Imutran Ltd
(Cambridge, United Kingdom)

Imutran, a Novartis Pharma AG Company, focused on xenotransplantation research and development within a pharmaceutical industry environment. Dr Schuurman headed the research in models of pig-to-nonhuman primate organ transplantation (in-house working party of ~20FTE) and was member of the management team supervising multiple external collaborations focusing on translating the research production into clinical application, as well as the close-down of the company initiated in 2000.

1992-1999 Head of Laboratory, Head of Unit and Program 'Transplantation in nonhuman primates'
Preclinical Research/Immunology, Sandoz Pharma AG; since 1997 Transplantation Research, Novartis Pharma AG (Basel, Switzerland)

- Research: experimental animal research in pharmacologic models of immune-mediated disorders and transplantation; participation in drug discovery and development. Heading a laboratory of ~8 FTEs
- Operational and strategic management: member/leader of various multidisciplinary teams in drug evaluation; member implementation team of transplantation research during the CIBA-Sandoz merger to form Novartis; member of the Board of this Department; implementation and heading a program on transplantation in nonhuman primates; supervision of multiple external collaborations, member steering committees of external collaborations, with the task to support the smooth transition of research data to clinical applications. Heading a unit of ~30 FTEs in ~8 laboratories

1979-1992 Head Laboratory for Immunopathology; Management Section of Histochemistry and Electron Microscopy

Departments of Pathology and Internal Medicine, University Hospital and Faculty of Medicine, University of Utrecht (Utrecht, The Netherlands)

Consultant, Laboratory for Pathology

National Institute of Public Health and Environmental Protection (Bilthoven, The Netherlands)

- **Clinical service:** leading a 4-8 FTEs team in advanced histopathological diagnostics: fostering the function as a reference laboratory in immunophenotyping of lymphomas
- **Teaching:** Immunology program of the graduate study in Biology, Chemistry or Pharmacy, Faculty of Science; undergraduate program in Medicine and Medical Biology, Faculty of Medicine; MD and PhD students; postgraduate courses. Leading an European Union Erasmus student-exchange Programme
- **Supervision PhD students:** 7 PhD theses 1983-2001
- **Research:** (human) histophysiology of the immune system; clinico-pathologic aspects of (heart) transplantation, autoimmune disease and immunodeficiency including HIV-infection/AIDS; immunotoxicology in experimental animals; thymus-induced immune tolerance. (Co-)principal investigator in ~15 research projects funded by external sources.
- **Management:** member various training Committees, University of Utrecht; member Board of research programmes in Immunology and Infection, Faculty of Medicine; committee member and president dutch Society of Medical Scientific Investigators; member and president Committee for Standardisation Immunotyping of Hematological Oncology in the Netherlands; member and secretary Committee for Promotion of Medical Immunology; vice president International Neighbour Group, University of Utrecht

1977-1979 Post-doctoral research

Department of Gastroenterology, University Hospital and Faculty of Medicine, University of Utrecht (Utrecht, The Netherlands)

- Research: heading team (3 FTEs) working on autoimmune liver diseases

Other

- Member Editorial Board Thymus (1989-1995), Section Editor Immune-mediated Diseases
- Member Editorial Board Toxicology (2006-), World Journal of Diabetes (2010-), Journal of Translational Internal Medicine (2014-)
- Member Editorial Board Transplantation Technology (2013-2015), Senior Editor (2013-2015)
- Member Editorial Board Xenotransplantation (2006-), Associate Editor (2009-)
- Guest Editor, European Journal of Pharmacology (2015)
- Visiting professorship in Pathology, Shanghai 1st Medical University, China (1989)
- Full Professor, Adjunct Faculty, Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA (2003-2004)
- Membership of organizing committees of various (international) scientific meetings
- Panel member, international evaluation of research in oncology and immunology in Latvia, Danish Research Council, Riga, Latvia (1992)
- Expert in science/business review of various academic and company activities in xenotransplantation
- Expert reviewer of grant applications (Juvenile Diabetes Research Foundation; Medical Research Council)
- Ad-hoc reviewer for American Journal of Transplantation, Current Clinical Pharmacology, Clinical Transplantation, Transplantation, The Transplantation Society, Transplantation Technology, International Journal of Surgery, International Journal of Molecular Sciences, BioMed Research International, Indian Journal of Pharmaceutical Education and Research, Journal of Infectiology, Journal of Clinical Immunology, Molecular Pharmacology, Toxins, Comparative Medicine, Experimental Biology and Medicine, Clinical Microbiology Reviews, Expert Opinion on Drug Discovery, Virus Research, Viruses, Food and Chemical Toxicology, Journal of Diabetes Research, British Journal of Medicine and Medical Research, Annals of Transplantation, Medical Science Monitor, World Journal of Critical Care Medicine, World Journal of Clinical Cases, Accountability in Research, World Journal of Hepatology, World Journal of Immunology, World Journal of Pharmacology, World Journal of Transplantation, World Journal of Gastroenterology, World Journal of Gastrointestinal Endoscopy, World Journal of Methodology, World Journal of Stem Cells, Open Veterinary Journal, Journal of Visualized Experiments, Stem Cell Reviews and Reports
- (Co)-author of >420 publications in peer-reviewed international scientific journals or book chapters; 4 patent applications; >110 seminars, lectures, chairpersonships during international meetings, or courses on invitation